Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders

Abstract

Objective:

To assess the effectiveness of managed care plans that limited access to infusion biologics via a step therapy policy.     

Health state utility values associated with advanced gastric,oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review

Abstract

Objectives:

To systematically identify utility values associated with advanced gastric cancer (GC), oesophageal cancer (OC), or gastro-oesophageal junction (GEJ) cancer. Utility values relating to health states are an essential component for cost-utility analysis (CUA).     

Treatment cost of non-small cell lung cancer in three European countries: comparisons across France,Germany, and England using administrative databases

Abstract

Introduction:

Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ～ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment.     

The burden associated with neuropathic pain in Western Europe

Abstract

Background:

The purpose of this study is to assess the burden of neuropathic pain (NeP) on health-related quality-of-life (HRQoL), health status, employment status, absenteeism and presenteeism, and direct medical costs in Western Europe.     

A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus

Abstract

Objective:

To conduct a network meta-analysis (NMA) to assess the relative efficacy and safety of simeprevir, a second generation oral protease inhibitor (PI), compared to telaprevir and boceprevir in combination with pegylated interferon-α and ribavirin (PR) in patients with chronic hepatitis C.     

Costs and absence of HCV-infected employees by disease stage

Abstract

Objectives:

Quantify the costs and absenteeism associated with stages of the Hepatitis C virus (HCV).     

Utilities for asthma and COPD according to category of severity: a comprehensive literature review

Abstract

Background:

Asthma and chronic obstructive pulmonary disease (COPD) are incurable diseases that impact quality-of-life.     

Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement

Abstract

Objective:

Conduct a cost effectiveness analysis for the Paliperidone palmitate Research In Demonstrating Effectiveness (PRIDE) trial.     

Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model

Abstract

Objectives:

To project the cost-effectiveness of population-based echo screening to prevent rheumatic heart disease (RHD) consequences.     

Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis

Abstract

Objective:

To estimate the cost-effectiveness of ipilimumab (3?mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients.     

Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral

Abstract

Objective:

To compare hospitalizations and incidence of relapses among patients with schizophrenia initiating long-acting injectable (LAI) antipsychotics vs oral antipsychotics.     

Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study

Abstract

Objective:

To estimate direct medical costs for patients with tuberous sclerosis complex (TSC) and surgical resection of subependymal giant-cell astrocytoma (SEGA).     

Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension

Abstract

Objectives:

To assess factors associated with adherence to phosphodiesterase type 5 inhibitors (PDE5Is) in the management of pulmonary arterial hypertension (PAH).     

The effect of age and sex on cost of inpatient facility encounters among patients with multiple sclerosis

Abstract

Objective:

To explore the effect of age and sex on cost of all-cause and multiple sclerosis (MS)-related inpatient facility encounters.     

Prevalence and healthcare costs of obesity-related comorbidities: evidence from an electronic medical records system in the United States

Abstract

Objective:

This study estimated the economic burden of obesity-related comorbidities (ORCs) in the US, at both the person and population levels.     

Comparative effectiveness of pegfilgrastim,filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses

Abstract

Objective:

Few studies have compared the effectiveness of filgrastim (FIL), pegfilgrastim (PEG), and sargramostim (SAR) to reduce the risk of febrile neutropenia (FN) associated with myelosuppressive chemotherapy (M-CT). Two large commercial database analyses were separately conducted to examine the incidence of neutropenia-related and all-cause hospitalizations associated with FIL, PEG, and SAR prophylaxis for patients receiving M-CT for non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, or solid tumors.     

Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States

Abstract

Objective:

To identify the direct and indirect costs of hypoglycemia in patients with Type 1 or Type 2 diabetes mellitus (DM) in the US setting.     

Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis

Abstract

Objective:

To estimate cost per patient-year in response during 2 years following biologic initiation among patients with rheumatoid arthritis (RA).     

Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor

Abstract

Objective:

To compare healthcare resource utilization (HCRU) and healthcare costs in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) and treated with prasugrel or ticagrelor.     

Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy

Abstract

Background:

Atrial fibrillation (AF) is the most common cardiac rhythm disturbance in the US, with an estimated prevalence of 2.7–6.1 million persons in 2010.